PillRx only · Tablet · Oral
Atazanavir And Cobicistat
Brands: Evotaz · Atazanavir Sulfate + Cobicistat
1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US1 NDCs
1 active makers
1 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$51.964
Latest avg · Jul 22, 2026
-0%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
651
Rx · 2026 Q1
21K
Units dispensed
-26%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Nov 3, 2025RESOLVEDShortage resolved: Atazanavir Sulfate; Cobicistat Tablet (Bristol Myers Squibb Co.)
Atazanavir Sulfate; Cobicistat Tablet — reported in shortage by Bristol Myers Squibb Co.. Therapeutic category: Antiviral.
- Nov 3, 2025SHORTAGEDrug shortage: Atazanavir Sulfate; Cobicistat Tablet (Bristol Myers Squibb Co.)
Atazanavir Sulfate; Cobicistat Tablet — reported in shortage by Bristol Myers Squibb Co.. Therapeutic category: Antiviral.